With the $62B Shire buy­out on track, Take­da plans to de­but the new­ly merged com­pa­ny at JP­Mor­gan

Af­ter spend­ing the last 6 months lin­ing up the nec­es­sary reg­u­la­to­ry OKs, Take­da CEO Christophe We­ber has sched­uled an up­com­ing share­hold­er vot­er need­ed to seal its $62 bil­lion deal to buy Shire. And afi­ciona­dos will note the time­line puts the close right in the mid­dle of the in­dus­try’s JP­Mor­gan gath­er­ing in ear­ly Jan­u­ary.

The US and Japan have al­ready of­fered their bless­ings to the buy­out, leav­ing Eu­rope ready to an­nounce its de­ci­sion by No­vem­ber 20. To get their sign off, Take­da agreed to spin out SHP647 along with “cer­tain as­so­ci­at­ed rights” where the EU saw an over­lap with its block­buster En­tyvio. 

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER